Most Read Articles
2 days ago
Age and sex do not appear to influence outcomes after percutaneous coronary intervention (PCI) or coronary-artery bypass grafting (CABG) for left main coronary artery disease, reports a recent study.
20 Jun 2019
Untreated white coat hypertension (WCH), but not treated white coat effect (WCE), may increase the risk for cardiovascular events and all-cause mortality, suggest the results of a systematic review and meta-analysis. Out-of-office blood pressure (BP) monitoring is thus important in the diagnosis and management of hypertension.
06 Aug 2019
Risk factors for 1-year mortality in heart failure (HF) patients significantly differ between those with and without chronic kidney disease (CKD), especially with regard to the use of beta-blockers or diuretics at discharge, according to a study. This suggests that these patients may benefit from individualized therapies.
23 Jun 2019
Implementing the 2017 American College of Cardiology/American Heart Association (ACC/AHA) guideline over that of the 2018 European Society of Cardiology/European Society of Hypertension (ESC/ESH) will give rise to a substantial increase in the prevalence of hypertension, as well as the number of adults who should receive medication, according to a study.

Product Highlight-Praluent

27 Sep 2018
PRALUENT – alirocumab 75 mg/mL and 150 mg/mL soln for inj - sanofi-aventis

• Praluent offers 2 starting doses to choose the power you need with 2 levels of LDL-C lowering
• Praluent helps to achieve rapid and sustained LDL-C reductions with:
- Praluent 75 mg offers powerful LDL-C reduction of >50%1
- Praluent 150 mg when >60% LDL-C reduction needed1

References:
1. In adults with primary hypercholesterolaemia (heterozygous familial and nonfamilial) or mixed dyslipidaemia, as an adjunct to diet: in combination with a statin or statin with other lipid lowering therapies in patients unable to reach LDL-C goals with the maximum tolerated dose of a statin or, alone or in combination with other lipid-lowering therapies in patients who are statin-intolerant, or for whom a statin is contraindicated.
2. References on file.


Further information is available in section 2l, New In This Issue and mims.com.
Full prescribing information is available upon request.




Related MIMS Drugs

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Cardiology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
2 days ago
Age and sex do not appear to influence outcomes after percutaneous coronary intervention (PCI) or coronary-artery bypass grafting (CABG) for left main coronary artery disease, reports a recent study.
20 Jun 2019
Untreated white coat hypertension (WCH), but not treated white coat effect (WCE), may increase the risk for cardiovascular events and all-cause mortality, suggest the results of a systematic review and meta-analysis. Out-of-office blood pressure (BP) monitoring is thus important in the diagnosis and management of hypertension.
06 Aug 2019
Risk factors for 1-year mortality in heart failure (HF) patients significantly differ between those with and without chronic kidney disease (CKD), especially with regard to the use of beta-blockers or diuretics at discharge, according to a study. This suggests that these patients may benefit from individualized therapies.
23 Jun 2019
Implementing the 2017 American College of Cardiology/American Heart Association (ACC/AHA) guideline over that of the 2018 European Society of Cardiology/European Society of Hypertension (ESC/ESH) will give rise to a substantial increase in the prevalence of hypertension, as well as the number of adults who should receive medication, according to a study.